ASX-shares of Mesoblast rise after back-treatment drug hits patent target

Mesoblast

29/04/2026 04:22

** Australian shares of Mesoblast MSB.AX rise as much as 4.2% to A$2.24, their biggest intraday pct gain since April 22

** Stock among the top gainers in Australia's S&P/ASX 200 index .AXJO, which is down 0.3%

** Stock set for a second consecutive session of gains, if current trend holds

** The drugmaker says its lower back-treating drug, rexlemestrocel-L, has achieved patient recruitment target

** The patent protects the drug from competition, supports higher long‑term revenues

** Despite moves, MSB down 17.8% YTD

 (Reporting by Aamir Sheik Khalid in Bengaluru)

 ((Aamir.SheikKhalid@thomsonreuters.com))